RAD December 2023 Abstracts and Posters
All accepted abstracts will be published in The British Journal of Dermatology.514 - Tapinarof cream 1% once daily: significant efficacy in the treatment of atopic dermatitis in two pivotal phase 3 trials in adults and children down to 2 years of age
Jonathan I. Silverberg, Lawrence F. Eichenfield, Adelaide A. Hebert, Eric Simpson, Linda Stein Gold, Robert Bissonnette, Kim A. Papp, John Browning, Pearl Kwong Neil J. Korman, Philip M. Brown, David S. Rubenstein, Stephen C. Piscitelli, Matthew C. Somerville, Anna M. Tallman, Leon Kircik
515 - Rapid and early onset of itch relief with tapinarof cream 1% once daily in two pivotal phase 3 trials in adults and children down to two years of age with atopic dermatitis
Eric Simpson, Jonathan I. Silverberg, Robert Bissonnette, Linda Stein Gold, April Armstrong, Adelaide A. Hebert, Rocco T. Serrao, Jeannette R. Jakus, Philip M. Brown, David S. Rubenstein, Stephen C. Piscitelli, Anna M. Tallman, Lawrence F. Eichenfield
516 - Comparative efficacy of targeted systemic therapies with topical corticosteroids for moderate-to-severe atopic dermatitis: an updated network meta-analysis
H Chih-ho Hong, April W Armstrong, Brian M Calimlim, Wan-Ju Lee, Henrique D Teixeira, Eric B Collins, Marjorie M Crowell, Scott J Johnson, Jonathan I Silverberg
517 - Lebrikizumab demonstrates significant efficacy versus placebo across racial and ethnic subgroups in patients with moderate-to-severe atopic dermatitis
Andrew Alexis, Michael Ardern-Jones, Raj Chovatiya, Carsten Flohr, Alan Irvine, Muna AlMurrawi, Amber Reck Atwater, Yuxin Ding, Meihua Qiao, Evangeline Pierce, Ignasi Pau-Charles, and Candrice Heath
518 - Interaction of sleep disturbance and nocturnal scratch in atopic dermatitis patients
Christos Alexopoulos, Alia Kassim, Yiorgos Christakis, Junrui Di, Kevin Thomas, Madisen Wicker, Nina Shaafi Kabiri, Walter Lehan, Sanford Auerbach, Carrie Northcott, John G Samuelsson
520 - Evaluating the expression of OX40 and OX40 ligand in lesional skin versus non-lesional skin in volunteers with atopic dermatitis and in healthy control skin
Stephan Weidinger, Thomas Watkins, Adrian Carr, Davide Lucchesi, Dora Stölzl, Natalie Rynkiewicz
522 - Efficacy and safety of abrocitinib in combination with topical therapy in adolescents from China with moderate-to-severe atopic dermatitis: A post hoc analysis of the JADE TEEN phase 3 trial
Zhirong Yao, Aie Xu, Li He, Yangfeng Ding, Guohong Hu, Shefali Vyas, Bo Wang, Xin Luo, Shiqi Li
523 - Efficacy and safety of amlitelimab (an anti-OX40 ligand antibody) in patients with moderate-to-severe atopic dermatitis: 24-week results from a Phase 2b trial (STREAM-AD)
Stephan Weidinger, Andrew Blauvelt, Kim Papp, Adam Reich, Chih-Hung Lee, Margitta Worm, Charles Lynde, Yoko Kataoka, Peter Foley, Christine Weber, Wanling Wong, Fabrice Hurbin, Natalie Rynkiewicz, Karl Yen, Xiaodan Wei, John T. O’Malley, Charlotte Bernigaud
524 - Efficacy of upadacitinib and dupilumab on achieving stringent and composite skin and itch outcomes: an indirect comparison of adults with moderate-to-severe atopic dermatitis
April W. Armstrong, H Chih-Ho Hong, Brian M Calimlim, Marric G Buessing, Marjorie M Crowell, Jonathan I Silverberg
525 - Real-world effectiveness of upadacitinib in moderate-to-severe atopic dermatitis (AD): Results from cross-sectional analyses of the CorEvitas AD Registry
Jonathan I Silverberg, Melinda Gooderham, Brian Calimlim, Ayman Grada, Yolanda Munoz Maldonado, Alvin Li, Margaux M. Crabtree, Eric Simpson